A 5mg vial of BPC-157 provides a standardized, high-purity lyophilisate engineered specifically for controlled in vitro and animal tissue repair assays. Designed for laboratory investigators evaluating cell migration and angiogenic pathways, this unit mass allows precise volumetric reconstitution and aliquot planning across diverse experimental protocols.
A 5mg vial of BPC-157 provides a standardized, high-purity lyophilisate engineered specifically for controlled in vitro and animal tissue repair assays. Designed for laboratory investigators evaluating cell migration and angiogenic pathways, this unit mass allows precise volumetric reconstitution and aliquot planning across diverse experimental protocols.
A 5mg vial of Body Protecting Compound 157 (BPC-157) represents a standard mass configuration utilized in preclinical research settings. Each sealed glass vial contains 5 milligrams of the synthetic pentadecapeptide in a lyophilized cake, combined with inert bulk carriers such as mannitol to ensure structural stability during vacuum drying and storage. Laboratories ordering this specific mass unit typically include academic research groups, biotechnology firms, and contract research organizations (CROs) conducting short-to-medium duration assays where precise mass management minimizes reagent degradation.
In laboratory workflows, the 5mg fill size serves as an ideal intermediate quantity. It provides sufficient peptide mass to run repeated in vitro assays or multi-subject animal model groups without requiring the frequent opening of larger bulk vials, which increases exposure to atmospheric moisture and risk of contamination. Investigators seeking to purchase this research compound can review availability via our BPC-157 product page or explore our complete catalog of high-purity items on the all peptides directory. PX1 Research ensures every fill size, including 5mg unit configurations, adheres to strict analytical testing parameters prior to release.
BPC-157 is categorized primarily as a tissue repair peptide. In preclinical rodent models and primary cell culture systems, the compound has been extensively evaluated for its role in accelerating the repair of compromised tissue structures, including tendons, ligaments, skeletal muscle, and gastrointestinal gut lining. Investigators focus on its capacity to promote vascular endothelial growth factor receptor 2 (VEGFR2) expression and activate downstream focal adhesion kinase (FAK) and paxillin pathways, which are vital for cell structural remodeling.
In vitro assays indicate that BPC-157 enhances endothelial cell migration, tube formation, and explant outgrowth without displaying direct mitogenic toxicity. Mouse and rat models of ischemic injury or surgical transection demonstrate that treatment with BPC-157 correlates with organized collagen deposition, increased capillary density (angiogenesis), and accelerated mucosal healing in gut lining injury models. These cellular processes make BPC-157 a pivotal reference molecule in musculoskeletal and gastroenterological preclinical research.
Accurate concentration calculations are vital when reconstituting a 5mg (5,000 micrograms) vial of BPC-157 for experimental use. Solubilization should always occur under a laminar flow hood using sterile diluents such as 0.9% sodium chloride, phosphate-buffered saline (PBS), or bacteriostatic water containing 0.9% benzyl alcohol. The final working concentration depends directly on the volume of diluent added to the vial.
Below are standard volumetric dilution profiles for a 5mg lyophilized vial: • 1.0 mL Diluent Volume: Reconstituting 5mg in 1.0 mL yields a final concentration of 5.0 mg/mL (or 5,000 µg/mL). In this configuration, every 0.01 mL (10 µL) pipetted volume delivers exactly 50 µg of peptide. • 2.0 mL Diluent Volume: Adding 2.0 mL of diluent lowers the concentration to 2.5 mg/mL (or 2,500 µg/mL). Each 0.01 mL (10 µL) aliquot contains 25 µg of BPC-157. • 3.0 mL Diluent Volume: Diluting with 3.0 mL yields a concentration of approximately 1.67 mg/mL (1,666.67 µg/mL). A 0.01 mL (10 µL) volume corresponds to approximately 16.67 µg.
To easily adjust parameters for alternate assay concentrations or custom pipetting protocols, researchers are encouraged to utilize our interactive reconstitution calculator. This tool helps prevent manual calculation errors during reagent preparation.
Once reconstituted, BPC-157 solution is vulnerable to physical degradation through repeat thermal cycles and mechanical shear stress. To maintain peptide integrity across multi-day cell culture or animal dosing trials, laboratory personnel should establish an immediate aliquoting protocol upon reconstitution. Rather than drawing repeatedly from the primary glass vial, the stock solution should be transferred into sterile, low-binding polypropylene microcentrifuge tubes in single-use working volumes.
For instance, if a experiment requires 250 µg of BPC-157 per culture plate daily, a 5mg vial reconstituted in 2.0 mL (2,500 µg/mL) can be divided into twenty 100 µL aliquots (containing 250 µg each). Working aliquots intended for use within 24 to 72 hours should be stored at 2°C to 8°C, while long-term reserve aliquots should be snap-frozen in liquid nitrogen and transferred to a -80°C freezer. This strategy limits freeze-thaw cycles to a single instance, protecting the pentadecapeptide's secondary structure and active binding sites.
Lyophilized BPC-157 exhibits high thermal stability when stored properly prior to reconstitution. Unopened vials sealed under inert nitrogen atmosphere should be maintained in a dark freezer at -20°C for standard storage, or -80°C for extended archival preservation exceeding 12 months. Desiccant packs should be kept in the storage container to prevent ambient humidity from penetrating the vial stopper over time.
Prior to introducing diluent, lyophilized vials must be allowed to equilibrate to room temperature (approximately 20°C to 22°C) for 20 to 30 minutes. Adding cold diluent to a cold vial can create vacuum pressure differentials and thermal shock, potentially disrupting the peptide matrix. Following reconstitution, solubilized BPC-157 must be kept refrigerated at 2°C to 8°C and protected from light. Exposure to ultraviolet light or room temperatures above 25°C leads to hydrolysis and gradual cleavage of the peptide chain.
PX1 Research enforces stringent analytical testing protocols for every lot of BPC-157 produced, regardless of fill mass. Every batch undergoes rigorous evaluation in an ISO 17025 accredited laboratory facility to verify identity, purity, and safety profile prior to release. High-Performance Liquid Chromatography (HPLC) is employed to confirm chemical purity, with PX1 setting a mandatory threshold of ≥98.0% purity.
Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular weight of BPC-157 (1419.5 Da), ensuring zero amino acid deletions or post-translational modifications occurred during solid-phase peptide synthesis (SPPS). Additionally, Chromogenic Limulus Amebocyte Lysate (LAL) testing is performed on every fill lot to guarantee endotoxin levels remain strictly below <0.01 EU/mg, preventing cell culture toxicity or non-specific inflammatory signaling in animal models. Researchers can review and download lot-matched certificates of analysis directly through our dedicated COA verification tool.
Selecting between a 5mg vial and alternative fill masses (such as 10mg or custom micro-dose units) depends on experimental scale, animal cohort size, and workflow schedule. For preliminary pilot studies, receptor-binding kinetics assays, or small-cohort rodent experiments, the 5mg vial size minimizes reagent waste by ensuring the entire reconstituted volume is consumed within its peak chemical stability window.
Conversely, high-throughput screening projects or long-term multi-week tissue regeneration studies may find 10mg vials or bulk ordering more economical and operationally efficient. Utilizing larger single-lot quantities reduces inter-assay variance across extended experiment timelines. Facilities planning large-scale research projects can explore bulk options and laboratory pricing structures via our wholesale portal.
In musculoskeletal and regenerative medicine research, BPC-157 is frequently evaluated alongside other prominent tissue repair compounds. Understanding how BPC-157 compares to agents like TB-500 (a synthetic fragment of Thymosin Beta-4) and GHK-Cu (a tripeptide-copper complex) provides key insights when designing comparative or synergistic tissue repair protocols.
While BPC-157 primarily target early-stage angiogenesis and VEGFR2-mediated cell migration, TB-500 works by sequestering monomeric G-actin to facilitate cell motility and tissue remodeling. GHK-Cu acts downstream by regulating gene expression of metalloproteinases and collagen synthesis. Preclinical studies suggest that combining agents targeting distinct mechanistic nodes can alter cellular migration rates in wound healing models. Researchers interested in exploring these biochemical mechanisms in depth can examine technical reports published in our research library.
All BPC-157 formulations provided by PX1 Research are manufactured in state-of-the-art, GMP-compliant facilities located within the United States. Utilizing automated solid-phase peptide synthesis platform technologies, PX1 maintains strict control over amino acid sequence assembly, counterion exchange, and final lyophilization. Every step of the production cycle is tracked to eliminate batch-to-batch variability.
By conducting final packaging and quality assurance in California and Arizona facilities, PX1 guarantees rapid distribution with same-day shipping on orders placed Monday through Friday. Researchers receive verified, cold-chain compliant compounds engineered exclusively for rigorous laboratory evaluation.
What is the exact molecular structure and weight of BPC-157?
BPC-157 is a 15-amino acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its calculated molecular weight is 1419.5 Da, confirmed via ESI-MS on every PX1 lot COA.
How do I calculate microgram concentration for a 5mg vial?
Concentration equals mass divided by volume. Diluting a 5mg (5,000 µg) vial with 1 mL diluent yields 5,000 µg/mL (5 µg/µL). Diluting with 2 mL yields 2,500 µg/mL (2.5 µg/µL), and 3 mL yields 1,666.67 µg/mL (~1.67 µg/µL).
How should unopened 5mg BPC-157 vials be stored upon arrival?
Unopened lyophilized vials should be stored at -20°C in a dark, desiccated environment. For storage exceeding 12 months, -80°C is recommended to preserve chemical stability.
What diluents are suitable for reconstituting BPC-157 for cell culture assays?
Sterile 0.9% sodium chloride, phosphate-buffered saline (PBS), or bacteriostatic water are appropriate diluents. Ensure the chosen vehicle is fully compatible with your specific cell line or assay conditions.
What purity level is verified on the PX1 BPC-157 Certificate of Analysis?
PX1 Research guarantees a chemical purity of ≥98.0% as determined by HPLC analysis. Endotoxin levels are confirmed at <0.01 EU/mg via chromogenic LAL testing.
Can reconstituted BPC-157 undergo multiple freeze-thaw cycles?
No. Repeated freeze-thaw cycles cause physical stress that leads to peptide bond cleavage and loss of activity. Aliquoting into single-use volumes immediately after reconstitution is strongly advised.
Is BPC-157 5mg intended for human therapeutic or clinical administration?
No. BPC-157 supplied by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical animal models). It is not for human or veterinary administration.
Where can I verify the lot-matched COA for my 5mg BPC-157 vial?
Lot-matched Certificates of Analysis can be accessed directly on the PX1 Research website by entering your vial's lot number into our online COA verification tool.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.